
<ns0:uwmetadata xmlns:ns0="http://phaidra.univie.ac.at/XML/metadata/V1.0" xmlns:ns1="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0" xmlns:ns10="http://phaidra.univie.ac.at/XML/metadata/provenience/V1.0" xmlns:ns11="http://phaidra.univie.ac.at/XML/metadata/provenience/V1.0/entity" xmlns:ns12="http://phaidra.univie.ac.at/XML/metadata/digitalbook/V1.0" xmlns:ns13="http://phaidra.univie.ac.at/XML/metadata/etheses/V1.0" xmlns:ns2="http://phaidra.univie.ac.at/XML/metadata/extended/V1.0" xmlns:ns3="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/entity" xmlns:ns4="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/requirement" xmlns:ns5="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/educational" xmlns:ns6="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/annotation" xmlns:ns7="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/classification" xmlns:ns8="http://phaidra.univie.ac.at/XML/metadata/lom/V1.0/organization" xmlns:ns9="http://phaidra.univie.ac.at/XML/metadata/histkult/V1.0">
  <ns1:general>
    <ns1:identifier>o:2953</ns1:identifier>
    <ns1:title language="en">Effect of DON and ZEN and their metabolites DOM-1 and HZEN on B cell proliferation and antibody production</ns1:title>
    <ns1:language>en</ns1:language>
    <ns1:description language="en">The mycotoxins deoxynivalenol (DON) and zearalenone (ZEN), produced by Fusarium fungi, are frequently found in the cereal-rich diet of pigs and can modulate the immune system. Some enzymes or bacteria present in the digestive tract can de-epoxydize DON to deepoxy-deoxynivalenol (DOM-1) and biotransform ZEN into hydrolyzed ZEN (HZEN). The effects of these metabolites on immune cells, particularly with respect to the vaccine responses, are poorly documented. The aim of this study was to address the impact of DON and ZEN and their respective derivatives, on proliferation, and antibody production of porcine B cells in vitro.Peripheral blood mononuclear cells (PBMCs), isolated from healthy pigs, were stimulated with the Toll-like receptor (TLR) 7/8-agonist Resiquimod (R848) or the TLR/1/2-agonist Pam3Cys-SKKKK in combination with DON [0.1-1.6 ÂµM] or DOM-1 [1.6 ÂµM and 16 ÂµM] and ZEN [2.5-40 ÂµM] or HZEN [40 ÂµM].A strong decrease in B-cell proliferation was observed at DON concentrations equal to or exceeding 0.8 ÂµM and at ZEN concentrations equal to or exceeding 20 ÂµM. Treatment with 1.6 ÂµM DON or 40 ÂµM ZEN led to almost a complete loss of live CD79Î±+ B cells. Moreover, CD21 expression of proliferating IgG+ and IgM+ B-cell subsets was decreased at DON concentrations equal to and exceeding 0.4 ÂµM and at ZEN concentrations equal to or exceeding 10 ÂµM. ELISpot assays revealed a decrease of IgG-secreting B cells at concentrations of and exceeding 0.4 ÂµM and at ZEN concentrations equal to and exceeding 10 ÂµM. ELISA assays showed a decrease of IgM, IgG, and IgA secretion at concentrations equal to or exceeding 0.4 ÂµM DON. ZEN reduced IgM secretion at 20-40 ÂµM (both R848 and Pam3Cys-SKKKK), IgG secretion at 40 ÂµM (both R848 and Pam3Cys-SKKKK) and IgA secretion at 20-40 ÂµM.Our in vitro experiments show that while DON and ZEN impair immunoglobulin production and B-cell proliferation, this effect is abrogated by HZEN and DOM-1.</ns1:description>
    <ns1:keyword language="en">Animals; Swine; Zearalenone; Antibody Formation; Leukocytes, Mononuclear; Cell Proliferation; Adjuvants, Immunologic; Enzyme-Linked Immunospot Assay; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Trichothecenes</ns1:keyword>
    <ns2:identifiers>
      <ns2:resource>1552099</ns2:resource>
      <ns2:identifier>10.3389/fimmu.2024.1338937</ns2:identifier>
    </ns2:identifiers>
  </ns1:general>
  <ns1:lifecycle>
    <ns1:upload_date>2024-05-07T13:33:53.282Z</ns1:upload_date>
    <ns1:status>44</ns1:status>
    <ns2:peer_reviewed>yes</ns2:peer_reviewed>
    <ns1:contribute seq="0">
      <ns1:role>46</ns1:role>
      <ns1:entity seq="0">
        <ns3:firstname>Alix</ns3:firstname>
        <ns3:lastname>Pierron</ns3:lastname>
        <ns3:institution>University of Veterinary Medicine Vienna</ns3:institution>
      </ns1:entity>
      <ns1:entity seq="2">
        <ns3:firstname>Alexandra</ns3:firstname>
        <ns3:lastname>Kleber</ns3:lastname>
        <ns3:institution>dsm-firmenich</ns3:institution>
        <ns3:type>person</ns3:type>
      </ns1:entity>
      <ns1:entity seq="3">
        <ns3:firstname>Elisabeth</ns3:firstname>
        <ns3:lastname>Mayer</ns3:lastname>
        <ns3:institution>dsm-firmenich</ns3:institution>
        <ns3:type>person</ns3:type>
      </ns1:entity>
      <ns1:entity seq="1">
        <ns3:firstname>Wilhelm</ns3:firstname>
        <ns3:lastname>Gerner</ns3:lastname>
        <ns3:institution>University of Veterinary Medicine Vienna</ns3:institution>
        <ns3:type>person</ns3:type>
        <ns3:orcid>0000-0002-2431-5889</ns3:orcid>
      </ns1:entity>
    </ns1:contribute>
  </ns1:lifecycle>
  <ns1:technical>
    <ns1:format>application/pdf</ns1:format>
    <ns1:size>3838997</ns1:size>
    <ns1:location>https://phaidra.vetmeduni.ac.at/o:2953</ns1:location>
  </ns1:technical>
  <ns1:rights>
    <ns1:cost>no</ns1:cost>
    <ns1:copyright>yes</ns1:copyright>
    <ns1:license>16</ns1:license>
  </ns1:rights>
  <ns1:classification>
    <ns1:purpose>70</ns1:purpose>
  </ns1:classification>
  <ns1:organization>
    <ns8:hoschtyp>1552253</ns8:hoschtyp>
  </ns1:organization>
  <ns12:digitalbook>
    <ns12:name_magazine language="en">Frontiers in Immunology</ns12:name_magazine>
    <ns12:pagination>12</ns12:pagination>
    <ns12:volume>15</ns12:volume>
    <ns12:publisher>Frontiers Media Sa</ns12:publisher>
    <ns12:releaseyear>2024</ns12:releaseyear>
  </ns12:digitalbook>
</ns0:uwmetadata>
